Seeing Is Believing
Currently out of the existing stock ratings of Neil Chatterji, 37 are a BUY (94.87%), 2 are a HOLD (5.13%).
Analyst Neil Chatterji, carries an average stock price target met ratio of 58.85% that have a potential upside of 63.03% achieved within 266 days. Previously, Neil Chatterji worked at B. RILEY, STIFEL.
Neil Chatterji’s has documented 76 price targets and ratings displayed on 12 stocks. The coverage was on Healthcare, Consumer Cyclical sectors.
Most recent stock forecast was given on CLPT, Clearpoint Neuro at 18-Mar-2026.
Analyst best performing recommendations are on LFMD (LIFEMD).
The best stock recommendation documented was for LFMD (LIFEMD) at 5/19/2023. The price target of $3.5 was fulfilled within 32 days with a profit of $1.46 (71.57%) receiving and performance score of 22.37.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 24-Oct-2023
$18
$9.4 (109.30%)
$25
13 days ago
(29-Oct-2026)
5/6 (83.33%)
$7.31 (68.38%)
127
Buy Since 09-Jun-2026
$25
$16.4 (190.70%)
$16
4 months 24 days ago
(18-Jun-2026)
1/2 (50%)
$7.23 (40.69%)
8
Buy Since 08-Aug-2024
$20
$11.4 (132.56%)
$18
7 months 24 days ago
(18-Mar-2026)
3/4 (75%)
$10.39 (108.12%)
120
Buy Since 05-Apr-2022
$20
$1.52 (8.23%)
$18
7 months 25 days ago
(18-Mar-2026)
3/4 (75%)
$10.39 (108.12%)
297
Buy Since 18-Mar-2021
$30
$21.4 (248.84%)
$15
1 years 9 months 21 days ago
(21-Jan-2025)
2/4 (50%)
$11.58 (62.87%)
297